Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Qiagen ( (QGEN) ) has issued an announcement.
QIAGEN N.V. has published a notification of voting rights after the Dutch financial markets regulator AFM reported that Goldman Sachs Group Inc. holds an aggregate 2.92% interest in the company’s share capital and voting rights as of January 16, 2026. The position is composed of a mix of directly and indirectly held ordinary shares, warrants, call options, swaps, and convertible bonds, with 0.30% classified as real indirect holdings and 2.62% as potential indirect holdings, underscoring continued derivative-based exposure by a major global financial institution to QIAGEN’s equity. QIAGEN emphasized that it is not responsible for the accuracy of the AFM data, which is sourced directly from the regulator’s public register, but the disclosure nonetheless signals the presence of a sizeable, sophisticated shareholder that could influence liquidity and market perception of the stock.
The most recent analyst rating on (QGEN) stock is a Buy with a $62.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
QIAGEN N.V., based in Venlo, Netherlands, is a life sciences and diagnostics company whose shares are listed on multiple European exchanges, including Frankfurt, as well as on the NYSE and Swiss markets. The company is a notable player in the regulated markets for molecular diagnostics and sample preparation technologies, drawing interest from major institutional investors and active trading across several stock exchanges.
Average Trading Volume: 1,650,733
Technical Sentiment Signal: Buy
Current Market Cap: $11.47B
See more insights into QGEN stock on TipRanks’ Stock Analysis page.